Table 7.

Individuals in each group experiencing an adverse event

Symptom	IVIG (n=42)	Placebo (n=14)
Patients with at least one SAE [%]	4 [9.5]	4 [28.6]
Knee replacement surgery		1 [7.1]
Gastric antral vascular ectasia		1 [7.1]
Post surgery delirium and lumbar laminectomy	1 [2.4]
Stroke/middle cerebral artery infarct	1 [2.4]
Nausea and vomiting	1 [2.4]
Acute aggression		1 [7.1]
Possible seizure		1 [7.1]
Progressively severe Alzheimer’sdisease	1 [2.4]
Patients with at least one AE [%]	25 [59.5]	9 [64.3]
Microbleeds	6 [14.3]
Dizziness		1 [7.1]
Headache	1 [2.4]
Paraesthesia		1 [7.1]
Chills	1 [2.4]
Influenza-likei llness	1 [2.4]
Hypoaesthesia	1 [2.4]
Tremor	1 [2.4]
CSF white blood cell count increased		1 [7.1]
Muscle spasms	1 [2.4]
Atrial fibrillation		1 [7.1]
Procedural hypertension	1 [2.4]
Agitation		1 [7.1]
Actinickeratosis	1 [2.4]
Hyperkeratosis	1 [2.4]
Pruritus	1 [2.4]
Headache	2 [4.8]	1 [7.1]
Hypoaesthesia	1 [2.4]
Blood pressure fluctuation	1 [2.4]
Hypotension	1 [2.4]	1 [7.1]
AST increased	1 [2.4]
LDH increased	1 [2.4]
Hearing impaired	1 [2.4]
Dyspepsia	1 [2.4]
Post lumbar punctures yndrome	1 [2.4]
Haematuria	1 [2.4]
Infusion site extravasation	1 [2.4]
Fatigue	1 [2.4]
Pyrexia	1 [2.4]
Falls	1 [2.4]